Cost-Effectiveness of SGLT2 Inhibitors in a Real-World Population: A MICADO Model-Based Analysis Using Routine Data from a GP Registry

OBJECTIVE: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have been shown to reduce the risk of cardiovascular complications, which largely drive diabetes’ health and economic burdens. Trial results indicated that SGLT2i are cost effective. However, these findings may not be generalizable to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyu, Hoogenveen, Rudolf, El Alili, Mohamed, Knies, Saskia, Wang, Junfeng, Beulens, Joline W. J., Elders, Petra J. M., Nijpels, Giel, van Giessen, Anoukh, Feenstra, Talitha L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492753/
https://www.ncbi.nlm.nih.gov/pubmed/37300652
http://dx.doi.org/10.1007/s40273-023-01286-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492753/
https://www.ncbi.nlm.nih.gov/pubmed/37300652
http://dx.doi.org/10.1007/s40273-023-01286-3

Ejemplares similares